Scinai Immunotherapeutics Reports Strong Q1 Earnings with Significant Net Income Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: seekingalpha
- Revenue Growth: Scinai Immunotherapeutics reported Q1 revenue of $0.4 million, indicating a gradual recovery and growth potential in the market, despite still being in the early stages.
- Net Income Reversal: The company achieved a net income of $3.6 million, compared to a net loss of $1.6 million in the prior-year period, primarily due to a $6.2 million non-cash bargain purchase gain, showcasing the success of its acquisition strategy.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $3.1 million, a significant increase from $1.8 million as of December 31, 2025, enhancing its liquidity and operational capacity.
- Asset and Equity Growth: Total assets rose to $17.6 million, while shareholders' equity increased to $11.8 million, reflecting an improvement in the company's financial health and laying a foundation for future investments and expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNI
About SCNI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scinai Immunotherapeutics Reports Strong Q1 Earnings with Significant Net Income Growth
- Revenue Growth: Scinai Immunotherapeutics reported Q1 revenue of $0.4 million, indicating a gradual recovery and growth potential in the market, despite still being in the early stages.
- Net Income Reversal: The company achieved a net income of $3.6 million, compared to a net loss of $1.6 million in the prior-year period, primarily due to a $6.2 million non-cash bargain purchase gain, showcasing the success of its acquisition strategy.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $3.1 million, a significant increase from $1.8 million as of December 31, 2025, enhancing its liquidity and operational capacity.
- Asset and Equity Growth: Total assets rose to $17.6 million, while shareholders' equity increased to $11.8 million, reflecting an improvement in the company's financial health and laying a foundation for future investments and expansion.
See More
Scinai Appoints New Head of CDMO Operations
- Leadership Change: Scinai Immunotherapeutics has announced the appointment of Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026, aimed at enhancing the company's operational capabilities and market competitiveness in the biopharmaceutical sector.
- Extensive Industry Experience: Elmalem brings over 20 years of experience in the biotechnology and pharmaceutical industries, having held senior leadership roles at Merck and Sigma-Aldrich Millipore, where he oversaw engineering and operations across multiple countries, which is expected to provide valuable expertise to Scinai's CDMO platform.
- Transition and Integration Plan: The knowledge transfer process began on May 10, 2026, under the supervision of current site head Dr. Sylvia Kachalsky, ensuring operational continuity and effective transfer of responsibilities, with Kachalsky expected to retire later in 2026.
- Strategic Expansion: Scinai CEO Amir Reichman stated that Elmalem's addition will support the continued expansion and operational excellence of the Yavne CDMO facility, further driving the company's growth potential in the global biopharmaceutical market.
See More
Scinai Appoints New Head of CDMO Operations
- Leadership Change: Scinai Immunotherapeutics has appointed Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026, aimed at enhancing the company's operational capabilities and market competitiveness.
- Extensive Industry Experience: Elmalem brings over 20 years of experience in the biotechnology and pharmaceutical sectors, having held senior leadership roles at Merck and Sigma-Aldrich Millipore, where he oversaw engineering and operational activities across multiple regions, which is expected to add significant strategic value to Scinai's CDMO platform.
- Transition and Integration Plan: The knowledge transfer process began on May 10, 2026, under the supervision of current head Dr. Sylvia Kachalsky, ensuring operational continuity and effective transfer of responsibilities, with Kachalsky expected to begin her retirement leave following the transition.
- Commitment to Continued Growth: Scinai CEO Amir Reichman emphasized that Elmalem's addition will support the long-term growth and operational excellence of the Yavne CDMO facility, reflecting the company's strong confidence in future expansion and commercial collaboration.
See More
Scinai Immunotherapeutics to Lead Roundtable at Dermatology Drug Development Summit
- Strategic Roundtable: Scinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit in Amsterdam next week, featuring CEO Amir Reichman and R&D Operations Director Meital Portugal, focusing on how oral peptides and small molecule therapies may reshape the immunology landscape.
- Industry Challenges: The discussion will address key challenges in immunology and dermatology drug development, including pharmacokinetic variability, bioavailability limitations, treatment adherence, durability of response, and sustained disease modification, highlighting the urgent need for innovative therapies in the industry.
- Scientific Innovation Trends: CEO Amir Reichman emphasized that the immunology field is rapidly evolving, with scientific innovation increasingly focusing on durability, convenience, and accessibility, which will influence future treatment modality selection and underscore the potential competition and complementarity between oral therapies and biologics.
- Company Strategic Positioning: Scinai's participation reflects its commitment to innovative immunology approaches, including advanced biologic formats and differentiated cytokine-targeting strategies, aiming to drive the development of next-generation immunology therapies through active engagement in industry discussions.
See More
Scinai Immunotherapeutics Secures $2.61M in Securities Purchase Agreement
- Financing Agreement: Scinai Immunotherapeutics has signed a securities purchase agreement with institutional investors to sell 5.21 million American Depositary Shares (ADS) at $0.48 each, expected to generate approximately $2.61 million, enhancing liquidity for future growth initiatives.
- Warrant Issuance: The company will issue Series A and Series B warrants to purchase 5.21 million ADSs at exercise prices of $0.48 and $0.55, respectively, with terms of two and five years, which will further improve capital structure flexibility.
- Investor Incentives: Scinai has entered into a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 ADS warrants, in exchange for new warrants to purchase 458,621 ADSs, thereby boosting investor confidence and engagement.
- Planned Use of Funds: The company intends to utilize the net proceeds alongside existing cash resources to support the expansion of its Contract Development and Manufacturing Organization (CDMO) platform, advance customer programs, and selectively invest in its immunotherapy pipeline, demonstrating a strategic focus on future growth.
See More
Scinai Immunotherapeutics Completes Financing Agreement
- Financing Agreement Reached: Scinai Immunotherapeutics has entered into a securities purchase agreement with institutional investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 each, expected to generate approximately $2.61 million to support the expansion of its CDMO platform and immunotherapy pipeline investments.
- Warrant Inducement Arrangement: The company has also engaged in a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 existing warrants for cash, providing the investor with 458,621 new warrants, thereby enhancing liquidity.
- Strategic Growth Support: This financing will provide essential funding for advancing customer programs and expanding the CDMO platform, indicating the company's ongoing commitment to investment in the biopharmaceutical sector to enhance market competitiveness.
- Expected Transaction Completion: The transactions are anticipated to close around April 27, 2026, subject to customary closing conditions, reflecting the company's active engagement in capital markets and confidence in future growth.
See More
Scinai Immunotherapeutics Reports Strong Q1 Earnings with Significant Net Income Growth
- Revenue Growth: Scinai Immunotherapeutics reported Q1 revenue of $0.4 million, indicating a gradual recovery and growth potential in the market, despite still being in the early stages.
- Net Income Reversal: The company achieved a net income of $3.6 million, compared to a net loss of $1.6 million in the prior-year period, primarily due to a $6.2 million non-cash bargain purchase gain, showcasing the success of its acquisition strategy.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $3.1 million, a significant increase from $1.8 million as of December 31, 2025, enhancing its liquidity and operational capacity.
- Asset and Equity Growth: Total assets rose to $17.6 million, while shareholders' equity increased to $11.8 million, reflecting an improvement in the company's financial health and laying a foundation for future investments and expansion.
See More
Scinai Appoints New Head of CDMO Operations
- Leadership Change: Scinai Immunotherapeutics has announced the appointment of Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026, aimed at enhancing the company's operational capabilities and market competitiveness in the biopharmaceutical sector.
- Extensive Industry Experience: Elmalem brings over 20 years of experience in the biotechnology and pharmaceutical industries, having held senior leadership roles at Merck and Sigma-Aldrich Millipore, where he oversaw engineering and operations across multiple countries, which is expected to provide valuable expertise to Scinai's CDMO platform.
- Transition and Integration Plan: The knowledge transfer process began on May 10, 2026, under the supervision of current site head Dr. Sylvia Kachalsky, ensuring operational continuity and effective transfer of responsibilities, with Kachalsky expected to retire later in 2026.
- Strategic Expansion: Scinai CEO Amir Reichman stated that Elmalem's addition will support the continued expansion and operational excellence of the Yavne CDMO facility, further driving the company's growth potential in the global biopharmaceutical market.
See More
Scinai Appoints New Head of CDMO Operations
- Leadership Change: Scinai Immunotherapeutics has appointed Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026, aimed at enhancing the company's operational capabilities and market competitiveness.
- Extensive Industry Experience: Elmalem brings over 20 years of experience in the biotechnology and pharmaceutical sectors, having held senior leadership roles at Merck and Sigma-Aldrich Millipore, where he oversaw engineering and operational activities across multiple regions, which is expected to add significant strategic value to Scinai's CDMO platform.
- Transition and Integration Plan: The knowledge transfer process began on May 10, 2026, under the supervision of current head Dr. Sylvia Kachalsky, ensuring operational continuity and effective transfer of responsibilities, with Kachalsky expected to begin her retirement leave following the transition.
- Commitment to Continued Growth: Scinai CEO Amir Reichman emphasized that Elmalem's addition will support the long-term growth and operational excellence of the Yavne CDMO facility, reflecting the company's strong confidence in future expansion and commercial collaboration.
See More
Scinai Immunotherapeutics to Lead Roundtable at Dermatology Drug Development Summit
- Strategic Roundtable: Scinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit in Amsterdam next week, featuring CEO Amir Reichman and R&D Operations Director Meital Portugal, focusing on how oral peptides and small molecule therapies may reshape the immunology landscape.
- Industry Challenges: The discussion will address key challenges in immunology and dermatology drug development, including pharmacokinetic variability, bioavailability limitations, treatment adherence, durability of response, and sustained disease modification, highlighting the urgent need for innovative therapies in the industry.
- Scientific Innovation Trends: CEO Amir Reichman emphasized that the immunology field is rapidly evolving, with scientific innovation increasingly focusing on durability, convenience, and accessibility, which will influence future treatment modality selection and underscore the potential competition and complementarity between oral therapies and biologics.
- Company Strategic Positioning: Scinai's participation reflects its commitment to innovative immunology approaches, including advanced biologic formats and differentiated cytokine-targeting strategies, aiming to drive the development of next-generation immunology therapies through active engagement in industry discussions.
See More
Scinai Immunotherapeutics Secures $2.61M in Securities Purchase Agreement
- Financing Agreement: Scinai Immunotherapeutics has signed a securities purchase agreement with institutional investors to sell 5.21 million American Depositary Shares (ADS) at $0.48 each, expected to generate approximately $2.61 million, enhancing liquidity for future growth initiatives.
- Warrant Issuance: The company will issue Series A and Series B warrants to purchase 5.21 million ADSs at exercise prices of $0.48 and $0.55, respectively, with terms of two and five years, which will further improve capital structure flexibility.
- Investor Incentives: Scinai has entered into a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 ADS warrants, in exchange for new warrants to purchase 458,621 ADSs, thereby boosting investor confidence and engagement.
- Planned Use of Funds: The company intends to utilize the net proceeds alongside existing cash resources to support the expansion of its Contract Development and Manufacturing Organization (CDMO) platform, advance customer programs, and selectively invest in its immunotherapy pipeline, demonstrating a strategic focus on future growth.
See More
Scinai Immunotherapeutics Completes Financing Agreement
- Financing Agreement Reached: Scinai Immunotherapeutics has entered into a securities purchase agreement with institutional investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 each, expected to generate approximately $2.61 million to support the expansion of its CDMO platform and immunotherapy pipeline investments.
- Warrant Inducement Arrangement: The company has also engaged in a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 existing warrants for cash, providing the investor with 458,621 new warrants, thereby enhancing liquidity.
- Strategic Growth Support: This financing will provide essential funding for advancing customer programs and expanding the CDMO platform, indicating the company's ongoing commitment to investment in the biopharmaceutical sector to enhance market competitiveness.
- Expected Transaction Completion: The transactions are anticipated to close around April 27, 2026, subject to customary closing conditions, reflecting the company's active engagement in capital markets and confidence in future growth.
See More
